AU
UK
CA
NZ
IND
US
Picard Medical, Inc. (NYSE:PMI), the parent company of SynCardia Systems LLC, is preparing to showcase new benchtop performance data for its fully implantable Emperor Total Artificial Heart (TAH) at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support (ISMCS 2025). The …
Autolus Therapeutics plc (NASDAQ:AUTL) announced that the National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending AUCATZYL (obecabtagene autoleucel) for adults aged 26 years and older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). With this decision, …
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) announced that the European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 years and older who do not respond adequately to histamine-1 antihistamines and are naïve …
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company advancing a cell-based platform for the targeted delivery of therapeutic payloads in oncology, has released new data from its ongoing TEM-GBM study in newly diagnosed glioblastoma multiforme patients with an unmethylated MGMT promoter. As of the …
Sangamo Therapeutics (NASDAQ:SGMO) announced that the U.S.Food and Drug Administrationhas accepted its request for a rollingBiologics License Applicationsubmission for isaralgagene civaparvovec, the company's investigational gene therapy for adults with Fabry disease. A rolling submission allows the FDA to review sections of the application as …
Eli Lilly and Co. (NYSE:LLY) briefly became the first healthcare company in the world to reach avaluationof USD 1 trln, a milestone that underscores the accelerating growth of the global metabolic health and weight-loss treatment market.
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. announced that the U.S.Food and Drug Administrationhas granted approval for PADCEV (enfortumab vedotin-ejfv) in combination with Merck’s Keytruda (pembrolizumab) or Keytruda QLEX. The therapy is now cleared for perioperative use in adults with muscle-invasive bladder cancer (MIBC) …
Gilead Sciences (NASDAQ:GILD) has completed the acquisition of the TREX1 cancer program from Sprint Bioscience AB. The agreement includes an upfront payment of USD 14 million and future potential milestone payments that could reach as high as USD 400 million.
Veeva Systems (NYSE:VEEV) reported a meaningful revenue increase for its fiscal third quarter ended October 31, 2025, supported by steady demand for its cloud-based solutions tailored to the life sciences sector. Totalrevenuerose 16%year-over-yearto USD 811.2 million, compared with USD 699.2 million in Q3 FY25. …
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) has initiated its Phase 3 CAREFNDR clinical trial evaluating paltusotine in adults with carcinoid syndrome, marking a major step toward expanding the therapeutic reach of its flagship drug. Carcinoid syndrome affects roughly 20 percent of people with neuroendocrine tumors, most …
Please wait processing your request...